Praxis Precision Medicines stock (US74006W1036): shares fall after mixed POWER1 epilepsy trial data

Praxis Precision Medicines shares on Nasdaq in the United States are under pressure after the company reported that its Phase 2/3 POWER1 study of vormatrigine in focal onset seizures did not meet the primary endpoint, even as a key secondary measure and safety profile remained supportive.

Praxis Precision Medicines shares on the Nasdaq in the United States came under renewed pressure after the company reported on 06/01/2026 that its Phase 2/3 POWER1 study of vormatrigine in focal onset seizures did not achieve the primary endpoint, prompting a program reassessment while the broader precision neuroscience pipeline remains in focus, according to a company press release published via GlobeNewswire on 06/01/2026 and a related Form 8-K filed with the SEC on the same day.Praxis press release as of 06/01/2026SEC Form 8-K as of 06/01/2026

The company, headquartered in Boston in the United States and listed on Nasdaq under the ticker PRAX, disclosed that the POWER1 trial in highly refractory focal onset seizures did not meet its primary endpoint of percent change in monthly seizure frequency, although a key secondary endpoint, the 50% responder rate, was reached and higher seizure reduction signals were observed at the 30 mg dose in the second half of the study, while vormatrigine was generally well tolerated with adverse event-related discontinuations below 10% and about 90% of treated patients entering and remaining in the open-label extension.StockTitan summary as of 06/01/2026

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Praxis Precision Medicines
• Sector/industry: Biopharmaceuticals / CNS neuroscience
• Headquarters/country: Boston, United States
• Core markets: United States and other major neurology markets
• Key revenue drivers: Future commercial potential of CNS therapies targeting tremor, epilepsy and other neurological disorders
• Home exchange/listing venue: Nasdaq (PRAX)
• Trading currency: USD

Praxis Precision Medicines: core business model

Praxis Precision Medicines focuses on developing targeted therapies for central nervous system disorders linked to imbalances in neuronal excitation and inhibition, with value creation expected to hinge on successfully advancing late-stage candidates toward regulatory approvals and commercialization.

Latest quarterly results for Praxis Precision Medicines at a glance

For context alongside the POWER1 update, investors continue to refer back to the most recently reported quarterly figures, where Praxis Precision Medicines detailed its financial position and R&D spending trends for its CNS pipeline in an earlier update, including the ongoing investments behind vormatrigine, ulixacaltamide and relutrigine, according to company information and coverage from sector-focused news services.Praxis investor relations

While the latest POWER1 topline results were not accompanied by fresh income statement figures, the update underlined that the company intends to concentrate resources on preparing potential launches for relutrigine and ulixacaltamide, indicating that future earnings trajectories will be closely tied to regulatory outcomes and commercialization timelines for these lead assets, according to commentary summarizing management’s remarks on 06/01/2026.Investing.com note as of 06/01/2026

Conclusion

The latest data from the POWER1 study in the United States mark a setback for vormatrigine’s current trial design, with the failure to meet the primary endpoint weighing on Praxis Precision Medicines stock even as safety and a key secondary responder measure offered some support. At the same time, management’s focus on advancing relutrigine and ulixacaltamide underscores that upcoming regulatory decisions and launch preparations for these CNS candidates are likely to play a central role in shaping future financial performance and investor sentiment toward the Nasdaq-listed company.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.